» Articles » PMID: 32986721

Locally Invasive, Castrate-resistant Prostate Cancer in a Pten/Trp53 Double Knockout Mouse Model of Prostate Cancer Monitored with Non-invasive Bioluminescent Imaging

Overview
Journal PLoS One
Date 2020 Sep 28
PMID 32986721
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Here we have improved an existing mouse model of prostate cancer based on prostate-specific deletion of Pten and Trp53 by incorporating a Cre-activatable luciferase reporter. By coupling the deletion of those genes to the activation of a luciferase reporter, we were able to monitor tumor burden non-invasively over time. We show that, consistent with previous reports, deletion of both Pten and Trp53 on a C57BL/6 background accelerates tumor growth and results in both the loss of androgen receptor expression and castrate resistant tumors as compared with loss of Pten alone. Loss of Trp53 results in the development of sarcomatoid histology and the expression of markers of epithelial-to-mesenchymal transition Zeb1 and vimentin, with kinetics and penetrance dependent on whether one or both alleles of Trp53 were deleted. Homozygous deletion of Trp53 and Pten resulted in uniformly lethal disease by 25 weeks. While we were able to detect locally invasive disease in the peritoneal cavity in aggressive tumors from the double knockout mice, we were unable to detect lymphatic or hematogenous metastatic disease in lymph nodes or at distant sites.

Citing Articles

Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development.

Lyu C, Vaddi P, Elshafae S, Pradeep A, Ma D, Chen S Oncogene. 2024; 44(5):322-335.

PMID: 39537875 DOI: 10.1038/s41388-024-03224-9.


Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.

Kaushal J, Takkar S, Batra S, Siddiqui J Cancer Lett. 2024; 593:216954.

PMID: 38735382 PMC: 11799897. DOI: 10.1016/j.canlet.2024.216954.


Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.

Chaudagar K, Hieromnimon H, Khurana R, Labadie B, Hirz T, Mei S Clin Cancer Res. 2023; 29(10):1952-1968.

PMID: 36862086 PMC: 10192075. DOI: 10.1158/1078-0432.CCR-22-3350.


In Vivo Models for Prostate Cancer Research.

Adamiecki R, Hryniewicz-Jankowska A, Ortiz M, Li X, Porter-Hansen B, Nsouli I Cancers (Basel). 2022; 14(21).

PMID: 36358740 PMC: 9654339. DOI: 10.3390/cancers14215321.


Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss.

Mejia-Hernandez J, Keam S, Saleh R, Muntz F, Fox S, Byrne D Cell Death Dis. 2022; 13(9):777.

PMID: 36075907 PMC: 9465983. DOI: 10.1038/s41419-022-05211-y.

References
1.
Martin P, Liu Y, Pierce R, Abou-Kheir W, Casey O, Seng V . Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol. 2011; 179(1):422-35. PMC: 3123810. DOI: 10.1016/j.ajpath.2011.03.035. View

2.
Epstein J, Amin M, Beltran H, Lotan T, Mosquera J, Reuter V . Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38(6):756-67. PMC: 4112087. DOI: 10.1097/PAS.0000000000000208. View

3.
Ku S, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich Z . Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017; 355(6320):78-83. PMC: 5367887. DOI: 10.1126/science.aah4199. View

4.
Foltz C . Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999; 49(3):319-23. View

5.
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I . Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019; 116(23):11428-11436. PMC: 6561293. DOI: 10.1073/pnas.1902651116. View